Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | FUT4 | P22083 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22396454 | 0.87 | HDAC1 (0.47) | HDAC1HDAC6LMNAKDM4ECA12 | |
| SCHEMBL31702195 | 0.85 | HDAC1 (0.46) | HDAC1HDAC6LMNAKDM4ECA12 | |
| SCHEMBL16064373 | 0.85 | TPMT (0.54) | HDAC1HDAC6LMNAKDM4ECA12 | |
| SCHEMBL19131129 | 0.85 | HDAC1 (0.46) | HDAC1HDAC6LMNAKDM4ECA12 | |
| SCHEMBL19067551 | 0.85 | TTR (0.52) | HDAC1HDAC6LMNAKDM4ECA12 | |
| Hydrochloric Acid SCHEMBL11629282 | 0.83 | TTR (0.50) | HDAC1HDAC6LMNAKDM4ECA12 | |
| Hydrochloric Acid SCHEMBL11625991 | 0.83 | TTR (0.50) | HDAC1HDAC6LMNAKDM4ECA12 | |
| SCHEMBL939977 | 0.82 | HDAC1 (0.61) | HDAC1HDAC6LMNACA1CA2 | |
| SCHEMBL19151611 | 0.82 | HDAC1 (0.43) | HDAC1HDAC6LMNAKDM4ECA12 | |
| SCHEMBL27817866 | 0.80 | HDAC1 (0.42) | HDAC1HDAC6LMNAKDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113173865-B | Graphene synergistic heat storage composite material driven by visible light and preparation method and application thereof | 山西大同大学 | 2023-03-28 | — | — | CN | claimed |
| CN-108947782-B | Bromofluoride multi-substituted benzaldehyde derivative and preparation method thereof | 上海罕道医药科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-113173865-A | Graphene synergistic heat storage composite material driven by visible light and preparation method and application thereof | 山西大同大学 | 2021-07-27 | — | — | CN | claimed |
| WO-2026101423-A1 | PHOTOSWITCHABLE CHEMICAL INDUCED DIMERIZATION SYSTEMS FOR CONTROL OF CELLULAR ACTIVITIES WITH LIGHT | WU YAOWEN (SE) | 2026-05-15 | — | — | WO | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-115197131-B | Azo 2-aminonicotinic acid benzyl ester derivative and preparation method and application thereof | 华东理工大学 | 2024-12-03 | — | — | CN | disclosed |
| US-12084448-B2 | Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne | SYNAFFIX B.V. (NL) | 2024-09-10 | — | — | US | disclosed |
| CN-111166744-B | Use of 4- (benzothiazol-2-yl) arylamine compound for treating gastric cancer | 诺丁汉大学 | 2024-06-25 | — | — | CN | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-7674912-B2 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2010-03-09 | — | — | US | disclosed |
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
| WO-2009138438-A1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES | N.V. ORGANON (NL) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| EP-1877391-A1 | PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES | H. Lundbeck A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | disclosed |
| WO-2006114093-A1 | PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | FFAR2, FFAR3, FFAR1 | HDAC1 2227/4885HDAC6 1563/4885LMNA 2645/4885 |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA2B, ADORA1 | HDAC1 1474/4885HDAC6 784/4885LMNA 453/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | HDAC1 1799/4885HDAC6 1644/4885LMNA 3756/4885 |
| US-12084448-B2 | Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne | AHR, CYP1B1, NAT1 | HDAC1 1062/4885HDAC6 2182/4885LMNA 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.